Ready to play
Ready to play
A team of researchers at the University of California, Los Angeles, has developed an experimental drug called "AD-NP1" which has received approval from the U.S. Food and Drug Administration (FDA) to begin clinical trials. The goal is to treat kidney damage. Research shows that this drug inhibits the enzyme "ENPP1," which hampers tissue repair processes and leads to declining kidney function. It has been proven to improve kidney functions and reduce scar tissue formation in tests on affected mice. Researchers expect that this medication will help accelerate kidney tissue healing and enhance the performance of damaged kidneys.
Notice: This Is an AI-Generated Summary
Comments (0)